Screener
ADMA Biologics ADMA BIVIGAM — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| (in thousands) | ||||
| ASCENIV | $$102,921 | $83,321 | $200,407 | 159,653 |
| BIVIGAM | 19,419 | 37,710 | 34,841 | 71,222 |
| Intermediates and other(1) | 1,297 | 917 | 2,130 | 4,790 |
| ADMA BioManufacturing | 123,637 | 121,948 | 237,378 | 235,665 |
| Plasma Collection Centers | 723 | - | 1,439 | 1,050 |
| License revenue | 35 | 36 | 71 | 71 |
| Total | $$124,395 | $121,984 | $238,888 | 236,786 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's BIVIGAM — revenue?
- ADMA Biologics (ADMA) reported BIVIGAM — revenue of $19.42M in Q2 2026.
- How has ADMA Biologics's BIVIGAM — revenue changed year-over-year?
- ADMA Biologics's BIVIGAM — revenue decreased by 48.5% year-over-year, from $37.71M to $19.42M.
- What does BIVIGAM — revenue mean?
- This metric represents the total gross revenue generated from the sale of the BIVIGAM product line, excluding any taxes collected from customers. It serves as a primary indicator of market demand and commercial adoption for this specific plasma-derived therapeutic. Monitoring this figure helps investors assess the product's contribution to the company's overall top-line growth and its competitive positioning within the immunodeficiency treatment market.
Ask your AI about ADMA Biologics's bivigam — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude